TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30279345

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Vigorous-Intensity Continuous Training (VICT)
Number of subjects: 11
Study: 28577672

Group type: EXPERIMENTAL
Intervention: Carillon Mitral Contour System (device)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nonimplanted)
Number of subjects: 0
Study: 26273747

Group type: EXPERIMENTAL
Intervention: Levobupivacaine plus dexmedetomidine (20 μg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Levobupivacaine alone
Number of subjects: 60
Study: 23858718

Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 0
Study: 20878665

Group type: EXPERIMENTAL
Intervention: Exercise Group (6 weeks movement training)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control Group (standard care)
Number of subjects: 27
Study: 19406340

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 50
Study: 17332177

Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella vaccine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mumps vaccine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rubella vaccine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pre-vaccination status
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Post-vaccination status
Number of subjects: 32
Study: 15107189

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 45

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 45
Study: 11498212

Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg twice daily
Number of subjects: 424

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Cilomilast 5 mg and 10 mg
Number of subjects: 424
Study: 9862014

Group type: EXPERIMENTAL
Intervention: Acupoint (Zusanli acupoints)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acupoints formula (Zusanli and Shousanli acupoints)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-acupoint (2 cm lateral to Zusanli acupoints)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acupoint vs Acupoints formula
Number of subjects: 13
Study: 8867157

Group type: EXPERIMENTAL
Intervention: Silicone intraocular lenses (90 D, Adatomed or C 10, Chiron)
Number of subjects: 815

Group type: COMPARATOR
Intervention: One-piece PMMA intraocular lens
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: All three types of IOLs
Number of subjects: 815
Study: 1690481

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Paraprost
Number of subjects: 156
Study: 7416907

Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 105
Study: 31789950

Group type: EXPERIMENTAL
Intervention: FibroTest in type-2 diabetes
Number of subjects: 505

Group type: COMPARATOR
Intervention: FibroTest in controls
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: SteatoTest-2 in type-2 diabetes
Number of subjects: 505

Group type: COMPARATOR
Intervention: SteatoTest-2 in controls
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: NashTest-2 in type-2 diabetes
Number of subjects: 505

Group type: COMPARATOR
Intervention: NashTest-2 in controls
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Transient elastography
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Magnetic resonance elastography
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: FibroTest
Number of subjects: 505
Study: 30422909

Group type: EXPERIMENTAL
Intervention: Objective risk score (CalcR) provided to intervention arm participants
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (no objective risk score provided)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 171
Study: 27500370

Group type: EXPERIMENTAL
Intervention: Aqueous solutions of surfactants (anionic, non-ionic, amphoteric)
Number of subjects: 20
Study: 25867693

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Self-help CBT-I (written materials only)
Number of subjects: 41
Study: 25930115

Group type: EXPERIMENTAL
Intervention: Povidone iodine ointment (PIO) applied starting on post-vaccination day 7
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no PIO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Povidone iodine ointment (PIO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Povidone iodine ointment (PIO) and control group
Number of subjects: 60
Study: 23220343

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention program (3-month duration including 8 weeks of exercise training, health education, home hazards evaluation/modification, medication review, and specialty consults)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention program
Number of subjects: 616

Group type: COMPARATOR
Intervention: Control group (health education brochures, referrals, and recommendations without direct exercise intervention)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 616
Study: 21241789

Group type: EXPERIMENTAL
Intervention: Controlled-release microparticles F-3 (TmH:EC ratio 1:2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled-release microparticles F-4 (TmH:EC ratio 1:3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release formulation (control)
Number of subjects: 0
Study: 17611168

Group type: EXPERIMENTAL
Intervention: Physical Activity Across the Curriculum (PAAC) intervention, incorporating moderate-intensity PA into standard academic lessons, with a target of 90-100 min/week over 3 years.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group, which did not alter their teaching methods.
Number of subjects: 22
Study: 16492621

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 47
Study: 12970142

Group type: EXPERIMENTAL
Intervention: Protein and energy dense supplement enriched with n‐3 fatty acids and antioxidants (E)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Isocaloric isonitrogenous control supplement (C)
Number of subjects: 200
Study: 10852980

Group type: EXPERIMENTAL
Intervention: Supervised 12-week aerobic exercise class
Number of subjects: 74

Group type: COMPARATOR
Intervention: Unsupervised home aerobic exercises
Number of subjects: 74
Study: 9515594

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (i.v.IG) 1 g/kg body weight
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (intravenous human serum albumin)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (i.v.IG)
Number of subjects: 31
Study: 8036475

Group type: EXPERIMENTAL
Intervention: loracarbef (200 mg b.i.d. for 7 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: amoxicillin (500 mg t.i.d. for 7 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: loracarbef
Number of subjects: 80

Group type: COMPARATOR
Intervention: amoxicillin
Number of subjects: 80
Study: 3177262

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MTC)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Domperidone (DMP)
Number of subjects: 44
Study: 31154414

Group type: EXPERIMENTAL
Intervention: TCZ mono (Tocilizumab monotherapy)
Number of subjects: 79

Group type: COMPARATOR
Intervention: TCZ + MTX (Tocilizumab plus Methotrexate)
Number of subjects: 79
Study: 29705650

Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Guideline-directed medical and device therapy alone (Control)
Number of subjects: 140
Study: 28893234

Group type: EXPERIMENTAL
Intervention: 3 hours removal of urinary catheter and vaginal pack
Number of subjects: 200

Group type: COMPARATOR
Intervention: 24 hours removal of urinary catheter and vaginal pack
Number of subjects: 200
Study: 26666374

Group type: EXPERIMENTAL
Intervention: Light-emitting diode therapy (LEDT) administered with a multidiode cluster probe (50 GaAIA LEDs, 850 ηm, 75 mW each diode, and 3 J per point) before exercise sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 23257316

Group type: EXPERIMENTAL
Intervention: Intralesion injections of pingyangmycin in combination with triamcinolone acetonide
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intralesion injections of pingyangmycin alone
Number of subjects: 29
Study: 21989212

Group type: EXPERIMENTAL
Intervention: Minimal acupuncture for two seconds in LI4, administered during six visits to the clinic, twice weekly.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no acupuncture).
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Minimal acupuncture for two seconds in LI4.
Number of subjects: 90
Study: 18070940

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 1902
Study: 16181792

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12701865

Group type: EXPERIMENTAL
Intervention: 5 IU/cc of low molecular weight heparin (LMWH) in vitrectomy infusion fluid
Number of subjects: 30

Group type: COMPARATOR
Intervention: No heparin in the infusion fluid (control group)
Number of subjects: 30
Study: 11120505

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Norethindrone acetate
Number of subjects: 51
Study: 9229416

Group type: EXPERIMENTAL
Intervention: Multimodality therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perioperative management
Number of subjects: 0
Study: 7982870

Group type: EXPERIMENTAL
Intervention: Juvenile Fire Awareness and Intervention Program (education about fire safety and behavior modification)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 138
Study: 3292159

Group type: EXPERIMENTAL
Intervention: 3 percent topical minoxidil solution applied twice daily for one year to half the scalp
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30612532

Group type: EXPERIMENTAL
Intervention: Self-compassion interventions
Number of subjects: 0
Study: 30952572

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: lacto‐ovo‐vegetarian diet (VD)
Number of subjects: 80
Study: 28991759

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 40
Study: 25617224

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (400,000 IU)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment
Number of subjects: 44
Study: 23782178

Group type: EXPERIMENTAL
Intervention: Clopidogrel (0.2 mg/kg/day)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 906
Study: 21416132

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy with streptokinase (SK)
Number of subjects: 120
Study: 18493312

Group type: EXPERIMENTAL
Intervention: gatifloxacin (10 mg/kg/day)
Number of subjects: 358

Group type: COMPARATOR
Intervention: azithromycin (20 mg/kg/day)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: gatifloxacin
Number of subjects: 358

Group type: COMPARATOR
Intervention: azithromycin
Number of subjects: 358
Study: 16790698

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (≤2 mg/kg/day)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 12955185

Group type: EXPERIMENTAL
Intervention: Uniplas
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Octaplas
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no plasma transfusion)
Number of subjects: 84
Study: 11203631

Group type: EXPERIMENTAL
Intervention: Cerec inlay
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Empress inlay
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gold inlay
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ceramic inlays (all types)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All ceramic systems
Number of subjects: 20
Study: 9361375

Group type: EXPERIMENTAL
Intervention: L-Arginine infusion
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oral L-Arginine supplementation
Number of subjects: 2
Study: 1558413

Group type: EXPERIMENTAL
Intervention: Intragastric misoprostol (200 micrograms four times a day)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Bolus intravenous cimetidine (300 mg every 6 hours)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Presence of renal failure
Number of subjects: 127

Group type: COMPARATOR
Intervention: Presence of hepatic failure
Number of subjects: 127

Group type: COMPARATOR
Intervention: Presence of coagulopathy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Number of organ system failures at study entry
Number of subjects: 127

Group type: COMPARATOR
Intervention: Presence of adult respiratory distress syndrome (ARDS)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Development of upper gastrointestinal hemorrhage (UGIH)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Number of stress lesions developed
Number of subjects: 127

Group type: COMPARATOR
Intervention: Additional organ system failure
Number of subjects: 127

Group type: COMPARATOR
Intervention: Diffuse gastritis
Number of subjects: 127
Study: 2983304

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia by the caudal route
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anaesthesia with halothane
Number of subjects: 0
Study: 30736748

Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM™) intervention
Number of subjects: 83
Study: 28786012

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 60
Study: 26621366

Group type: EXPERIMENTAL
Intervention: FastFES
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fast
Number of subjects: 50

Group type: COMPARATOR
Intervention: Self-selected speeds (SS)
Number of subjects: 50
Study: 24790277

Group type: EXPERIMENTAL
Intervention: 75 mg amitriptyline
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 22925596

Group type: EXPERIMENTAL
Intervention: cCBT with brief phone support by assistant (5-10 min)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: cCBT with extended phone support by assistant (20-30 min)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: cCBT with brief phone support by clinician (5-10 min)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: cCBT with extended phone support by clinician (20-30 min)
Number of subjects: 200
Study: 19809337

Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 800 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Risperidone (up to 6 mg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 22
Study: 17906160

Group type: EXPERIMENTAL
Intervention: Single 200 mg dose of pirfenidone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Single 400 mg dose of pirfenidone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Single 600 mg dose of pirfenidone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Multiple doses of 400 mg pirfenidone administered 3 times daily (tid)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pirfenidone with food
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pirfenidone without food (fasted)
Number of subjects: 48
Study: 16044340

Group type: EXPERIMENTAL
Intervention: Capecitabine (1,250 mg/m2 twice daily for 14 days, followed by a 7-day rest period, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5‐FU/LV (Mayo Clinic regimen: LV 20 mg/m2 followed by 5‐FU 425 mg/m2, administered as an i.v. bolus on days 1‐5 every 28 days, n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5‐FU/LV
Number of subjects: 20
Study: 12402370

Group type: EXPERIMENTAL
Intervention: Educational program focused on coping with residual and relapse warning signs, managing drug side effects, medication compliance, and daily routines; included self-efficacy method, manuals, videotapes, small group discussions, and telephone coaching
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 38
Study: 10464459

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Open surgery (laparotomy)
Number of subjects: 6000
Study: 7781143

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg i.v. before paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Famotidine 20 mg i.v. before paclitaxel
Number of subjects: 0
Study: 2189483

Group type: EXPERIMENTAL
Intervention: Arthroscopic operation using laser
Number of subjects: 140

Group type: COMPARATOR
Intervention: Arthroscopic operation using mechanical instruments
Number of subjects: 140
Study: 7273650

Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: TBI (Total Body Irradiation)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy (stratified for Stage III)
Number of subjects: 114
Study: 29294507

Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen (IVA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (PCA alone)
Number of subjects: 82
Study: 28651211

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 43
Study: 26062183

Group type: EXPERIMENTAL
Intervention: Three-spasm-needle therapy applied to Jiejian, Xuehaishang and Houxuehai, given once every two days for 20 days, with 3 sessions total.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional physical therapies (Bobath therapy and lower extremities therapy) and scalp acupuncture (seven‐intelligent needles) in the control group, given once every day for 20 days, with 3 sessions total.
Number of subjects: 140
Study: 23415239

Group type: EXPERIMENTAL
Intervention: Medicare
Number of subjects: 10854

Group type: EXPERIMENTAL
Intervention: Medicaid
Number of subjects: 10854

Group type: EXPERIMENTAL
Intervention: No insurance
Number of subjects: 10854

Group type: COMPARATOR
Intervention: Private insurance
Number of subjects: 10854
Study: 21214919

Group type: EXPERIMENTAL
Intervention: DECISION+ continuing medical education program
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: DECISION+ training sessions
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire based on Azjen's Theory of Planned Behaviour
Number of subjects: 39
Study: 19551404

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 15

Group type: COMPARATOR
Intervention: Running
Number of subjects: 15
Study: 17108817

Group type: COMPARATOR
Intervention: Endoscopic discectomy alone
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Endoscopic discectomy combined with 1000 U chymopapain
Number of subjects: 280
Study: 15657472

Group type: EXPERIMENTAL
Intervention: 8 % carbohydrate-electrolyte beverage
Number of subjects: 36

Group type: COMPARATOR
Intervention: 6 % carbohydrate-electrolyte beverage
Number of subjects: 36
Study: 11696050

Group type: COMPARATOR
Intervention: Ultrasonic nebulizer with low output of 0.87 mL/min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizer with high output of 1.90 mL/min
Number of subjects: 18
Study: 9130894

Group type: EXPERIMENTAL
Intervention: Gonadotropin-stimulated cycle
Number of subjects: 18
Study: 7709771

Group type: EXPERIMENTAL
Intervention: Surgibone (animal bone substitute harvested from steers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous bone graft
Number of subjects: 0
Study: 2897516

Group type: COMPARATOR
Intervention: Standard anticoagulant control with rabbit brain thromboplastin (therapeutic range 18‐24 s; INR 2.5‐40)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Less intensive regimen controlled with human brain thromboplastin (therapeutic range 26‐30 s; INR 2.0‐2.25)
Number of subjects: 210
Study: 29467523

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone
Number of subjects: 100
Study: 27626182

Group type: EXPERIMENTAL
Intervention: Escitalopram (N = 127)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo (N = 128)
Number of subjects: 255
Study: 24449007

Group type: EXPERIMENTAL
Intervention: Somatosensory electrical stimulation to the paretic foot during a targeted stepping task
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Somatosensory electrical stimulation to the paretic foot
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Somatosensory electrical stimulation
Number of subjects: 12
Study: 23552131

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) + Optimal Medical Therapy (OMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 0
Study: 20131031

Group type: EXPERIMENTAL
Intervention: lamivudine combined with SPNS
Number of subjects: 160

Group type: COMPARATOR
Intervention: lamivudine only (Control)
Number of subjects: 160
Study: 18678611

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281